DeutschNewstral
Article
bizjournals.com on 2021-05-14 14:17
Emergent BioSolutions setbacks cause J&J vaccine supply to dwindle
Related news
- Emergent BioSolutions setbacks cause J&J vaccine supply to dwindlebizjournals.com
- Emergent BioSolutions calls J&J vaccine manufacturing error 'disappointing'bizjournals.com
- Emergent BioSolutions calls J&J vaccine manufacturing error at Baltimore facility 'disappointing'bizjournals.com
- What J&J’s Covid-19 vaccine situation means for Maryland’s Emergent BioSolutionsbizjournals.com
FDA OK's Emergent BioSolutions plant to resume manufacturing J&J's Covid vaccineCNN
J&J vaccine supply has run out; Emergent says it’s working on improvementsArs Technica- MEmergent BioSolutions inks coronavirus vaccine manufacturing deal with J&Jmarketwatch.com
Emergent BioSolutions (EBS) OversoldForbes
Emergent BioSolutions expands Baltimore facilitythedailyrecord.com- Inside Emergent BioSolutions’ Covid-19 vaccine strategybizjournals.com
Wingstop, Guess rise; CarMax, Emergent BioSolutions fallSeattle Times- BJ&J Will Manufacture Its Own Vaccine at Emergent Facility Where Doses Were Ruinedbarrons.com
- MJ&J to pay Emergent $135 million as part of COVID-19 vaccine manufacturing dealmarketwatch.com
J&J vaccine production could restart in U.S. 'within days,' Emergent executive testifiesPOLITICO- FDA orders J&J contractor Emergent to stop vaccine production during inspectionPOLITICO
Coronavirus: US firm Emergent admits to issues with J&J vaccine affecting millions of dosesSouth China Morning Post- After ruining 75M J&J doses, Emergent gets FDA clearance for 25M dosesArs Technica
- Emergent BioSolutions grows profit, revenue in 2017thedailyrecord.com
- Emergent BioSolutions to spin off biosciences companybizjournals.com